Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Haleon is the world's largest standalone consumer health company, spun off from GSK in July 2022, with a portfolio of category-leading brands including Sensodyne (oral health), Advil/Panadol (pain relief), Centrum (vitamins), and Theraflu (respiratory). The company operates across 170+ markets with ~60% of revenue from emerging markets and North America, competing primarily on brand equity and distribution scale rather than patent protection. Stock performance is driven by organic revenue growth (pricing power and volume), margin expansion from post-spin operational efficiencies, and capital allocation decisions given its strong FCF generation.
Haleon monetizes brand equity built over decades through premium pricing versus private label alternatives, typically commanding 20-40% price premiums. The business model relies on high gross margins (60%+) from low manufacturing costs relative to retail prices, offset by significant A&P spending (12-14% of sales) to maintain brand strength. Distribution is critical - the company leverages relationships with major retailers (Walmart, CVS, Boots) and e-commerce platforms to secure shelf space. Pricing power stems from consumer trust in established brands for health-related purchases where switching costs are behavioral rather than economic. The company benefits from category growth in emerging markets as middle-class consumers trade up from unbranded products.
Organic revenue growth rate - particularly volume growth versus pricing mix, as sustained volume declines signal brand weakness
Emerging markets performance - China, India, Brazil represent high-growth opportunities but face execution risks and FX headwinds
Margin expansion trajectory - ability to reduce A&P as % of sales while maintaining market share demonstrates brand strength
Capital allocation decisions - M&A appetite for bolt-on brands, dividend policy (targeting 30-50% payout), and share buyback authorization
Competitive dynamics in oral health - Sensodyne faces pressure from Colgate's premium launches and private label innovation
Regulatory changes - potential Rx-to-OTC switches (e.g., statins, diabetes drugs) could expand addressable market or create new competition
Private label encroachment - retailer own-brands gaining quality parity in categories like pain relief and vitamins, particularly as retailers invest in premium private label positioning
Regulatory risk of Rx-to-OTC switches - while potentially expanding markets, could introduce well-funded pharma competitors with clinical data advantages
E-commerce disruption - Amazon's push into private label health products and direct-to-consumer brands bypassing traditional retail could erode distribution advantages
Demographic headwinds in developed markets - aging populations support some categories (denture care, joint pain) but younger consumers show less brand loyalty
Procter & Gamble and Johnson & Johnson have deeper pockets for A&P spending and can leverage broader consumer product portfolios for cross-promotion
Reckitt Benckiser competes directly in pain relief (Nurofen) and respiratory (Mucinex) with similar scale and emerging market presence
Bayer's consumer health division (Aspirin, Claritin, Aleve) overlaps significantly in pain relief and allergy categories
Niche disruptors in VMS category (e.g., Ritual, Care/of) using DTC models and personalization to attract younger consumers
Current ratio of 0.87 indicates working capital tightness, though typical for consumer goods companies with negative cash conversion cycles
Pension obligations inherited from GSK could require future cash contributions if discount rates decline or asset returns disappoint
FX exposure is substantial with ~50% of revenue outside USD/GBP - hedging program mitigates near-term volatility but not long-term translation effects
Contingent liabilities from Zantac litigation (ranitidine) remain, though Haleon's exposure is limited compared to GSK's retained liabilities
low-to-moderate - Consumer health products are relatively non-discretionary with stable demand through cycles, but premium-to-private-label mix shifts occur during recessions. Pain relief and oral health are defensive, while VMS (vitamins/minerals/supplements) shows more discretionary characteristics. Emerging market exposure (40%+ of sales) creates sensitivity to local GDP growth and currency fluctuations. Historical evidence shows 0.3-0.5x beta to consumer spending - volumes hold up but trading down pressures margins.
Rising rates have modest negative impact through two channels: (1) higher discount rates compress valuation multiples for stable-growth consumer staples, and (2) stronger dollar from rate differentials creates FX translation headwinds given significant non-USD revenue. Debt load is manageable (0.54x D/E) so financing costs are not material. The company benefits from higher rates on cash balances (~£2B+ cash position). Primary sensitivity is valuation multiple compression as bond yields rise and income-seeking investors rotate from dividend stocks.
Minimal - business model is cash-generative with limited working capital needs. Retailer credit risk is diversified across thousands of customers. No meaningful exposure to consumer credit conditions as products are low-ticket, immediate-consumption items. Investment-grade credit rating (Baa2/BBB) provides ample access to capital markets.
value and dividend - The stock appeals to income-focused investors seeking stable, growing dividends (3%+ yield) backed by predictable cash flows. Post-spin valuation discount to peers (P/E ~15-17x vs. 20x+ for pure-play consumer health) attracts value investors betting on multiple re-rating as standalone track record builds. Low correlation to economic cycles makes it a defensive allocation for risk-averse portfolios. Limited appeal to growth investors given mid-single-digit organic growth profile and mature category exposure.
low-to-moderate - Beta estimated at 0.6-0.8 based on consumer staples comparables. Daily volatility is muted by defensive business characteristics, but stock experienced elevated volatility in 2022-2023 post-spin as investor base transitioned from GSK holders to dedicated consumer health investors. Currency volatility creates quarterly earnings variability. Liquidity has improved since spin with average daily volume ~$150M, reducing volatility from large block trades.
